Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Collegium Pharma (COLL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 633,745
  • Shares Outstanding, K 33,250
  • Annual Sales, $ 28,480 K
  • Annual Income, $ -74,870 K
  • 36-Month Beta 0.29
  • Price/Sales 22.98
  • Price/Cash Flow N/A
  • Price/Book 9.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.36
  • Number of Estimates 3
  • High Estimate -0.28
  • Low Estimate -0.49
  • Prior Year -0.54
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.21 +26.23%
on 11/12/18
19.83 -3.18%
on 12/06/18
+3.78 (+24.51%)
since 11/09/18
3-Month
13.70 +40.15%
on 11/09/18
19.83 -3.18%
on 12/06/18
+3.34 (+21.06%)
since 09/10/18
52-Week
13.70 +40.15%
on 11/09/18
29.90 -35.79%
on 03/09/18
+1.50 (+8.47%)
since 12/08/17

Most Recent Stories

More News
Alternatives to Watch

HENDERSON, NV / ACCESSWIRE / December 10, 2018 / Below are several companies positioning themselves to be a viable opioid alternative.

CARA : 15.83 (-1.49%)
COLL : 19.20 (+0.73%)
TTNP : 0.28 (unch)
INSY : 5.14 (-0.77%)
ENDV : 0.0239 (-4.40%)
Relatively Good Performance Detected in Shares of Dermira in the Pharmaceuticals Industry (DERM , OMER , COLL , ENDP , ITCI )

Here are the top 5 stocks in the Pharmaceuticals industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

COLL : 19.20 (+0.73%)
DERM : 10.83 (-0.55%)
OMER : 13.85 (-1.21%)
Lannett Co Inc has the Best Relative Performance in the Pharmaceuticals Industry (LCI , COLL , HZNP , ZGNX , SUPN )

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

COLL : 19.20 (+0.73%)
LCI : 5.39 (+0.56%)
HZNP : 19.56 (-0.46%)
Collegium Pharma has the Best Relative Performance in the Pharmaceuticals Industry (COLL , ENDP , MDCO , AKRX , NKTR )

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

COLL : 19.20 (+0.73%)
ENDP : 11.35 (-1.90%)
MDCO : 20.79 (-2.62%)
Collegium Pharmaceutical (COLL) Reports Q3 Loss, Lags Revenue Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -127.27% and -6.94%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the...

COLL : 19.20 (+0.73%)
Collegium Pharmaceutical: 3Q Earnings Snapshot

CANTON, Mass. (AP) _ Collegium Pharmaceutical Inc. (COLL) on Thursday reported a loss of $16.5 million in its third quarter.

COLL : 19.20 (+0.73%)
Collegium Reports Third Quarter Financial Results

-- Net Product Revenues were $70.2 million for the third quarter of 2018, a 487% increase versus third quarter of 2017

COLL : 19.20 (+0.73%)
Collegium Pharmaceutical (COLL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

COLL : 19.20 (+0.73%)
Top 5 Companies in the Pharmaceuticals Industry with the Best Relative Performance (PETX , OMER , COLL , AERI , MYL )

Here are the top 5 stocks in the Pharmaceuticals industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

COLL : 19.20 (+0.73%)
PETX : 6.32 (-1.56%)
OMER : 13.85 (-1.21%)
Report: Exploring Fundamental Drivers Behind Continental Building Products, Hornbeck Offshore Services, Digi International, Triple-S Management, Collegium Pharmaceutical, and Cardiovascular -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Continental Building Products,...

COLL : 19.20 (+0.73%)
GTS : 18.91 (-0.84%)
CBPX : 26.90 (-0.11%)
DGII : 11.02 (+2.42%)
HOS : 2.55 (-5.20%)
CSII : 29.14 (+2.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade COLL with:

Business Summary

Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company's product candidate consists of COL-195, COL-196, COL-171,...

See More

Key Turning Points

2nd Resistance Point 20.07
1st Resistance Point 19.64
Last Price 19.20
1st Support Level 18.63
2nd Support Level 18.05

See More

52-Week High 29.90
Fibonacci 61.8% 23.71
Fibonacci 50% 21.80
Fibonacci 38.2% 19.89
Last Price 19.20
52-Week Low 13.70

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar